Authors
Ting Wu, Zhiyu Wu, Mengyi Li, Huajing Yu, Yating Huang, Xinyao Wang, Canqing Yu, Dianjianyi Sun, Pei Pei, Ling Yang, Iona Millwood, Robin Walters, Yiping Chen, Huaidong Du, Yuan Cao, Daniel Avery, Yang Liu, Peng Zhang, Junshi Chen, Zhengming Chen, Pang Yao, Jun Lv, Zhongtao Zhang, Liming Li, Yuanjie Pang, China Kadoorie Biobank Collaborative Group
Published in
Obesity (Silver Spring, Md.). Nov 15, 2026. Epub Nov 15, 2026.
Abstract
This study aimed to discover causal plasma proteins for metabolic dysfunction-associated steatotic liver disease (MASLD) using trans-ancestry genetic data.
We performed proteome-wide Mendelian randomization (MR) for 1256 proteins and MASLD using genome-wide association data from East Asian (n = 85,124) and European (n = 500,348) populations. Colocalization was conducted to validate putative causal proteins for MASLD, followed by two-step MR assessing adiposity mediation. Longitudinal cross-lagged analysis in a bariatric surgery cohort (n = 53) was used to assess temporal associations.
ENTPD5 and APOE showed consistent causal effects in both East Asians and Europeans, both supported by colocalization. Both proteins influenced MASLD risk through adiposity, with BMI mediating 15.7% of the ENTPD5 effect. Longitudinal analysis in the bariatric surgery cohort supported the temporal pathway "ENTPD5→BMI reduction→MASLD remission (assessed by the fatty liver index)," with 29.2% mediation by BMI. Phenome-wide MR revealed a broad pleiotropic profile of ENTPD5, warranting further evaluation of target safety and repurposing potential.
These findings suggest that ENTPD5 and APOE are potential causal biomarkers for MASLD and may contribute to its pathogenesis. ENTPD5 represents a candidate target for obesity-related diseases, although its pleiotropic profile warrants further investigation.
PMID:
43035253
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0